Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Dutasteride and Imidafenacin in BPH/OAB patients not respond to eight weeks'continuous treatment of Tamsulosin.

Trial Profile

Effect of Dutasteride and Imidafenacin in BPH/OAB patients not respond to eight weeks'continuous treatment of Tamsulosin.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imidafenacin (Primary) ; Dutasteride
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms DIrecT
  • Sponsors Kyorin Pharmaceutical
  • Most Recent Events

    • 16 Sep 2016 Results of subgroup analysis (n=163) presented at the 46th Annual Meeting of the International Continence Society.
    • 07 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 15 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top